{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:33:32Z","timestamp":1788489212668,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jdcr.2022.01.005","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T18:44:02Z","timestamp":1642617842000},"page":"140-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma"],"prefix":"10.1016","volume":"21","author":[{"given":"Christina D.","family":"Enescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Artz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Axelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"29","key":"10.1016\/j.jdcr.2022.01.005_bib1","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jdcr.2022.01.005_bib2","doi-asserted-by":"crossref","first-page":"621591","DOI":"10.3389\/fonc.2021.621591","volume":"11","author":"Viscuse","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jdcr.2022.01.005_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdcr.2020.10.020","article-title":"A rare presentation of enfortumab vedotin-induced toxic epidermal necrolysis","volume":"7","author":"Francis","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jdcr.2022.01.005_bib4","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D3252042890","article-title":"Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma","volume":"25","author":"Wu","year":"2019","journal-title":"Dermatol Online J"},{"issue":"12","key":"10.1016\/j.jdcr.2022.01.005_bib5","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/1346-8138.15577","article-title":"Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin","volume":"47","author":"Sasaki","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.jdcr.2022.01.005_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdcr.2021.05.020","article-title":"Cutaneous reactions with enfortumab vedotin: a case series and review of the literature","volume":"14","author":"Dobry","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"8","key":"10.1016\/j.jdcr.2022.01.005_bib7","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/jid.2014.119","article-title":"Nectin-4 mutations causing ectodermal dysplasia with syndactyly perturb the rac1 pathway and the kinetics of adherens junction formation","volume":"134","author":"Fortugno","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"10","key":"10.1016\/j.jdcr.2022.01.005_bib8","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.jdcr.2022.01.005_bib9","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.2014.56.2959","article-title":"EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer","volume":"33","author":"Yardley","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jdcr.2022.01.005_bib10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622000194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622000194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:23:27Z","timestamp":1762475007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512622000194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":10,"alternative-id":["S2352512622000194"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.01.005","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}